the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers
Official Title A Phase 2, Open-label Evaluation of CRS-207 and Pembrolizumab in Adults With Recurrent or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinomas
Principal Investigator Catenacci, Daniel
Brief Summary The purpose of this study is to determine whether CRS-207 in combination with pembrolizumab is safe and effective in adults with recurrent or metastatic gastric, gastroesophageal junction, or esophageal cancer who have received one or two prior systemic chemotherapy treatment regimens for advanced disease.
Gender All
Ages 18 Years
Enrollment 79
Accepts Healthy Volunteers No
Lead Sponsor Aduro Biotech, Inc.Industry
Collaborator Merck Sharp & Dohme Corp.Industry
Study Design
Study Phase Phase 2
Study Type Interventional
Contact Name Zev Wainberg, MD
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Gastric Adenocarcinoma
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI